Table 1.
Baseline Characteristics of HCV-Infected Patients Treated with IFN-Free Regimens.
| Parameter | All Patients, n = 963 |
|---|---|
| Gender, females/males, n (%) | 525 (54.5)/438 (45.5) |
| Age [years] mean ± SD; min.–max. | 50.4 ± 15.9; 19–89 |
| Median (Q1, Q3) | 50.0 (36.0, 63.0) |
| Females, age [years] mean ± SD; min.–max. | 52.1 ± 16.3; 19–88 |
| Median (Q1, Q3) | 55.0 (36.0, 65.0) |
| Males, age [years] mean ± SD; min.–max. | 48.4 ± 15.1; 19–89 |
| Median (Q1, Q3) | 45.0 (36.0, 60.0) |
| BMI [kg/m2] mean ± SD; min.–max. | 25.9 ± 4.5; 15.6–45 |
| Median (Q1, Q3) | 25.4 (22.6, 28.5) |
| GT, n (%) | |
| 1 | 34 (3.5) |
| 1a | 12 (1.3) |
| 1b | 797 (82.8) |
| 2 | 0 |
| 3 | 89 (9.2) |
| 4 | 29 (3) |
| 5 | 0 |
| 6 | 2 (0.2) |
| Comorbidities, n (%) | |
| Any comorbidity | 752 (78.1) |
| Hypertension | 337 (35) |
| Diabetes | 117 (12.1) |
| Renal disease | 82 (8.5) |
| Kidney failure–eGRF < 30 mL/min, 30–60 mL/min | 28 (2.9), 9 (0.9) |
| Dialysis | 6 (0.6) |
| Autoimmune diseases | 68 (7.1) |
| Non-HCC tumors | 52 (5.4) |
| Other | 663 (68.8) |
| Concomitant medications, n (%) | 621 (64.5) |
| Liver fibrosis, n (%) | |
| F0 | 43 (4.5) |
| F1 | 472 (49) |
| F2 | 139 (14.4) |
| F3 | 102 (10.6) |
| F4 | 207 (21.5) |
| HCC history, n (%) | 10 (1) |
| OLTx history, n (%) | 4 (0.4) |
| HBV coinfection (HBsAg+), n (%) | 7 (0.7) |
| HIV coinfection, n (%) | 2 (0.2) |
| Extrahepatic manifestations of HCV, n (%) | |
| Cryoglobulinemia | 446 (46.3) |
| Thyroid abnormalities with presence of anti-thyroid antibodies | 86 (8.9) |
| Thrombocytopenia in noncirrhotics | 38 (3.9) |
| Other | 17 (1.8) |
| History of previous therapy, n (%) | |
| Treatment-naive | 759 (78.8) |
| Non-responder | 79 (8.2) |
| Relapser | 78 (8.1) |
| Discontinuation due to safety reason | 47 (4.9) |
| ALT IU/L, mean ± SD | 72.4 ± 57.1 |
| Median (Q1, Q3) | 55.0 (35.0, 91.0) |
| Bilirubin mg/dL, mean ± SD | 0.9 ± 1 |
| Median (Q1, Q3) | 0.8 (0.6, 1.0) |
| Albumin g/dL, mean ± SD | 4 ± 0.4 |
| Median (Q1, Q3) | 4.1 (3.8, 4.3) |
| Creatinine mg/dL, mean ± SD | 1 ± 0.6 |
| Median (Q1, Q3) | 0.9 (0.8, 1.0) |
| Hemoglobin g/dL, mean ± SD | 14.3 ± 1.6 |
| Median (Q1, Q3) | 14.3 (13.3, 15.4) |
| Platelets, ×1000/µL, mean ± SD | 184.8 ± 71.4 |
| Median (Q1, Q3) | 186.0 (140.0, 228.5) |
| HCV RNA × 106 IU/mL, mean ± SD | 2.8 ± 8.6 |
| Median (Q1, Q3) | 1.0 (0.3, 2.8) |
ALT: alanine transaminase; BMI: body mass index; F: fibrosis; GT: genotype; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HCV RNA: ribonucleic acid of hepatitis C virus; HIV: human immunodeficiency virus; IFN: interferon; OLTx: orthotopic liver transplantation; SD: standard deviation.